Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NYSE:PFE

Pfizer Inc (PFE)

26.17
+0.57 (2.23%)
as of Jun 11, 2026, 8:00:00 pm Market Open.
322 watching
0
HOLD
Dividend over 6%. Would hold for the dividend. Wouldn’t buy.
HOLD
They’ve got lots of cash, therefore their dividend is safe. Not sure if they are going to be able to build their business to have significant growth.
BUY
Pretty cheap. Has been a dog over the last year but you are getting a 5.5% dividend. PE is 11X’s. Their patent on the Lipitor drug expires, but not for another 12 years. Cash flow from this is about 40% of their profit and they are moving into other new drugs. If the Democrats win, the question is will they get squeezed on Medicare but that is already built into the stock.
BUY
Trading at 10X earnings, which is the lowest he has ever seen a US pharmaceutical. They are great beneficiaries of the lower US$. Have a great international business. Have lots of cash for acquisitions.
BUY
(Market Call Minute.) At this price, you can be a buyer and sell at $26 or so.
TOP PICK
He has a model price of $40.10, which is a 76% positive differential. Has up its dividends considerably and has positive earnings revisions.
DON'T BUY
Their pipeline has just not produced new drugs. When you buy this stock now, you are getting a series of cash flows on the existing drugs, but a lot of them are coming off patent. Just acquired a company that has a very small drug, which to him, is a sign of desperation.
DON'T BUY
This is the worst of times for giant pharmaceutical companies. Now spending more on marketing than they are on research/development. Ongoing huge costs of developing new drugs that are safe are a drag. Also, cost of litigation remains a huge burden. Probably safer with the generic companies.
BUY
Has a 2-pronged approach to the drug industry with Teva Pharmaceuticals (TEVA-Q) as his growth generic company and this one as his value dividend play. It is giving great income until their pipeline improves.
PAST TOP PICK
(A Top Pick Feb 1/07. Down 10% including dividends.) This one has been the bane of all value managers. His model price is $37.57, a 66% positive differential. This one needs a catalyst.
PAST TOP PICK
(A Top Pick Dec 18/06. Down 7.4%.) Got decimated when they lost a lawsuit on Lipitor. Sold his holdings.
TOP PICK
This sector does well in a slowing economy. 5.6% yield. Has a war chest of almost $30 million in cash to be used for acquisitions. Share buybacks keep increasing the dividends. Mid/long-term pipeline is very promising. Yield and cash limit downside risk. A lot of potential upside surprises.
PAST TOP PICK
(A Past Top Pick Dec 21/06. Down 10.8%.) This one is probably the bane of all the value managers. Even boosted their dividend by 10%. His model price is $40.53, a 74% positive differential. If they could do anything to thin out that balance sheet, it would be a huge positive for the stock.
DON'T BUY
He threw in the towel last quarter and sold his holdings. The problem is they just haven't been developing new drugs and as time goes by, you get closer to patent expiration.
DON'T BUY
Big questions with drug companies are “How big is their pipeline of drugs and development?” “What’s the patent life of their big drugs?” and “How vulnerable are they to erosion from generics?”.
Showing 451 to 465 of 801 entries